Autoimmune diseases are thought to result from imbalances in normal immune physiology and regulation. Here, we show that autoimmune disease susceptibility and resistance alleles on mouse chromosome 3 (Idd3) correlate with differential expression of the key immunoregulatory cytokine interleukin-2 (IL-2). In order to test directly that an approximately twofold reduction in IL-2 underpins the Idd3-linked destabilization of immune homeostasis, we show that engineered haplodeficiency of Il2 gene expression not only reduces T cell IL-2 production by twofold but also mimics the autoimmune dysregulatory effects of the naturally occurring susceptibility alleles of Il2. Reduced IL-2 production achieved by either genetic mechanism correlates with reduced function of CD4 + CD25 + regulatory T cells, which are critical for maintaining immune homeostasis.
Autoimmune diseases are thought to result from imbalances in normal immune physiology and regulation. Here, we show that autoimmune disease susceptibility and resistance alleles on mouse chromosome 3 (Idd3) correlate with differential expression of the key immunoregulatory cytokine interleukin-2 (IL-2). In order to test directly that an approximately twofold reduction in IL-2 underpins the Idd3-linked destabilization of immune homeostasis, we show that engineered haplodeficiency of Il2 gene expression not only reduces T cell IL-2 production by twofold but also mimics the autoimmune dysregulatory effects of the naturally occurring susceptibility alleles of Il2. Reduced IL-2 production achieved by either genetic mechanism correlates with reduced function of CD4 + CD25 + regulatory T cells, which are critical for maintaining immune homeostasis.
Multifactorial diseases with high population prevalence develop as a result of interactions between multiple genetic and environmental factors. Since the early 1990s, several loci have been mapped by genetic linkage and association analyses in humans and in rodent models of autoimmune disease, including type 1 diabetes (T1D). T1D is caused by the destruction of the insulin-producing pancreatic beta cells by various immune cell types, including CD8 + T cells. In addition to HLA, five loci have been convincingly associated with susceptibility to T1D in humans: the gene encoding insulin, the negative immunoregulatory genes CTLA4 and PTPN22, the gene encoding the alpha chain of the interleukin-2 receptor (CD25) and the interferoninduced helicase 1 gene 1 . All of these common variants support the concept that autoimmunity is a part of normal physiology and that the balance between immune responses to foreign antigens and to self (the disruption of which sometimes leads to pathology) is dependent on a complex network of negative and positive feedback molecules and mechanisms shaped during evolution as an effective defense to infections.
Insulin-dependent diabetes 3 (Idd3), on mouse chromosome 3, has a major effect on T1D development in the nonobese diabetic (NOD) mouse model of T1D, promoting the infiltration of autoreactive lymphocytes into the pancreas 2, 3 . The Idd3 region also determines susceptibility to experimental autoimmune encephalomyelitis and autoimmune ovarian dysgenesis induced by neonatal thymectomy 4, 5 , a disease that is dependent on regulatory T cell function 6 . Using a positional cloning strategy, we have shown that Idd3 spans 780 kb and includes the IL-2 gene (Il2), which encodes a molecule critical for the maintenance of immune homeostasis 3 . Although we have hypothesized that Il2 is Idd3 (ref. 7) , the gene encoding IL-21 (Il21) is also a candidate for Idd3 (ref. 8) . The aim of the current study was to test the hypothesis that Il2 accounts for Idd3-mediated modulation of T1D.
RESULTS

Genetic analyses
To positionally clone the gene accounting for the Idd3 phenotype, we generated congenic NOD strains carrying progressively shorter intervals of B6-derived DNA. The first congenic strain we developed had approximately 85 Mb of B6 chromosome 3 DNA 2 . The region was subsequently narrowed to B780 kb by studying seven additional B6 Idd3 congenic strains 3 . Notably, the largest and smallest introgressed intervals conferred equivalent levels of T1D resistance. In the present study, we used additional polymorphic markers to narrow the Idd3 interval to B650 kb containing five known genes (Tenr, Il2, Il21, Cetn4 and Fgf2), two predicted genes of unknown function (KIAA1109 and KIAA1371) and three pseudogenes (see URLs listed in Methods and Supplementary Fig. 1 online) . BAC clone-based DNA sequence analyses demonstrated that the NOD and 129 Idd3 intervals are identical by descent (IBD) 9 (0.68 SNPs per 10 kb, with nearly all of these few SNPs in intragenic regions) throughout the portions of Idd3 that were sequenced from both strains (B250 kb). Our observation that NOD and 129 are IBD at Idd3 is consistent with the NOD-like T1D frequency of NOD.129 Idd3 congenic mice 7 . In contrast to the IBD pattern observed for the NOD/129 comparison, the B6 strain has a distinct sequence or haplotype, with approximately 100 SNPs per 10 kb throughout the Idd3 region ( Supplementary  Fig. 1 ), which includes nonsynonomous SNPs in exon 1 of Il2 that alter the glycosylation of IL-2 and could be the molecular basis of Idd3 (ref. 7) .
Because B6 and NOD/129 have a haplotypic difference throughout the 650-kb Idd3 region, we investigated the correlation between disease susceptibility and Idd3 SNPs by developing, phenotyping and sequencing congenic NOD mice carrying Idd3 DNA from four different inbred mouse strains. Of primary interest is the NOD.CZECH Idd3 strain, which has an Il2 exon 1 sequence and glycosylation pattern similar to that of NOD 7 and was therefore predicted to be susceptible to T1D. Unexpectedly, we found that NOD.CZECH Idd3 mice have a T1D frequency identical to that of NOD.B6 Idd3 mice (Fig. 1) , a result that does not support the hypothesis that a glycosylation difference accounts for the molecular basis of Idd3 (although it does not unambiguously disprove it). The NOD.A/J Idd3 and NOD.SWR Idd3 strains were developed because their IL-2 molecules are identical to that of NOD 7 , and the Idd3 region of the A/J strain predisposes to autoimmune ovarian dysgenesis 5 . The CAST strain from M. musculus castaneous, as well as the CZECH strain from M. musculus musculus, are derived from wild mice and thus have a greater diversity of sequence variants than inbred laboratory strains. In F2 segregation analyses of the NOD.SWR Idd3, NOD.CAST Idd3 and NOD.A/J Idd3 congenic strains, we found that mice homozygous for the non-NOD Idd3 region were as susceptible to T1D as their NOD homozygous littermates (Fig. 1) . We resequenced the two main candidate genes, Il2 and Il21, in this panel of T1D-susceptible strains (NOD, NOD.CAST Idd3, NOD.SWR Idd3, NOD.A/J Idd3 and NOD.129 Idd3) and resistant strains (NOD.CZECH Idd3, NOD.B6 Idd3 and NON, in which the resistance phenotype at Idd3 was determined in segregation analyses 10 ). However, disease-associated SNPs, defined as those shared by the susceptible strains but different from those found in the resistant strains, were numerous and found in or near both genes ( Supplementary Fig. 1 ). We did not identify any nonsynonymous coding or obvious splice site-changing SNPs; therefore, we evaluated the hypothesis that Idd3 corresponds to SNPs that alter production and/or stability of Il2 and/or Il21 transcripts.
Idd3 regulates Il2 transcription
We initially addressed the hypothesis of differential transcriptional control by examining the expression of Il2 mRNA in thymocytes, known to produce IL-2 under physiological conditions 11 . Thymocytes from T1D-susceptible NOD, NOD.129 Idd3 and NOD.CAST Idd3 Figure 1 Frequency of diabetes in Idd3-congenic NOD strains. Frequencies were compared in the new NOD.CZECH Idd3 congenic strain, the NOD.B6 Idd3 congenic strain (Taconic line 1098) and NOD mice. The diabetes phenotypes of the Idd3 alleles of CAST, SWR and A/J were determined by assessing the frequency of diabetes in F2 progeny generated from each strain using heterozygous breeders at the N6, N7 and N8 generations. Each figure includes mice homozygous for the NOD alleles and the non-NOD alleles at Idd3 as well as the heterozygous progeny. mice produced approximately twofold less Il2 mRNA than thymocytes from T1D-protected NOD.B6 Idd3 or NOD.CZECH Idd3 mice ( Supplementary Fig. 2 online) . Splenocytes of these mice had lower levels of Il2 mRNA, but we observed the same strain hierarchy in Il2 mRNA expression as in thymocytes (data not shown). Analysis of splenocytes from mice treated with monoclonal antibody to CD3 (anti-CD3) in vivo confirmed the above correlation ( Fig. 2a) : cells from T1D-resistant NOD.B6 Idd3 and NOD.CZECH Idd3 mice had more Il2 mRNA than those from T1D-susceptible NOD, NOD.A/J Idd3, NOD.SWR Idd3 and NOD.CAST Idd3 mice. In contrast to results from unstimulated thymocytes, splenocytes from NOD.CZECH Idd3 mice treated with monoclonal anti-CD3 contained higher levels of Il2 mRNA than NOD.B6 Idd3 splenocytes (Fig. 2a) , possibly reflecting differences in responsiveness of the corresponding Il2 alleles to endogenous stimuli versus responsiveness to monoclonal anti-CD3. We saw differential expression of Il2 in both CD4 + and CD8 + T cells ( Supplementary Fig. 3 online) . We did not see a correlation between Il21 mRNA levels and disease susceptibility or resistance (Fig. 2b) .
We developed a quantitative PCR assay for intron 2 of Il2 to assess pre-mRNA levels of Il2 transcripts and again observed genotypedependent expression differences (Fig. 2c) . Taken together, these results indicate that the Il2 genotype determines a difference in the proportion of cells producing Il2 mRNA and/or in the number of Il2 transcripts per cell, rather than differences in mature Il2 message stability. Allele-specific assays confirmed that the T1D-resistant B6 and CZECH Il2 haplotypes are transcriptionally more active than the NOD haplotype in splenic T cells from F1 mice treated with monoclonal anti-CD3 (Fig. 2d) . Once again, the CZECH Il2 allele appeared to be transcriptionally more active than the B6 Il2 allele. Analysis of RNA from monoclonal anti-CD3-treated B10.BR mice with and without a congenic NOD Idd3 region further indicated that allelic differences in expression are intrinsic to the Idd3 region and are not dependent on the diabetogenic NOD background (Supplementary Fig. 3 ).
To confirm these observations and to elucidate the cellular basis of Idd3, we introduced one or two copies of the B6 Idd3 region into transgenic NOD mice expressing a diabetogenic T cell receptor (TCR) (referred to as 8.3-NOD mice) 12 . This TCR is representative of a large fraction of islet-associated CD8 + T cells in NOD mice that use highly homologous TCRa chains [12] [13] [14] and recognize the mimotope NRP-A7 in the context of H-2K d (ref. 15 ). These T cells are already a significant component of the earliest NOD islet CD8 + infiltrates [14] [15] [16] , they are pathogenic 12, 13 , they target a peptide from islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP 206-214 , similar to NRP-A7) 17 and they are unusually frequent in the periphery 17, 18 .
The B6 Idd3 haplotype afforded highly significant protection from T1D in 8.3-NOD mice (Fig. 3a) . Cytofluorometric studies of 8.3-NOD and 8.3-NOD.B6 Idd3 mice (referred to as 8.3-NOD.Idd3 B6/B6 ) indicated that the B6 Idd3 haplotype does not interfere with the development of 8.3-CD8 + T cells ( Supplementary Fig. 4 online) . At the functional level, the splenic CD8 + T cells of both types of mice proliferated equally well and secreted similar levels of interferon gamma (IFN-g) in response to antigen ( Fig. 3b and data not shown). Notably, however, 8.3-CD8 + T cells purified from the spleens of 8.3-NOD.Idd3 B6/B6 mice consistently secreted higher levels of IL-2 and produced higher levels of Il2 mRNA upon peptide stimulation than those purified from 8.3-NOD mice (Fig. 3b,c) . We observed these differences with both NRP-A7 and IGRP 206-214 peptides, over a range of concentrations and at different times after activation ( Fig. 3b and data not shown). We obtained similar results when we stimulated the T cells with peptide-MHC monomers or with monoclonal anti-CD3 plus monoclonal anti-CD28 ( Supplementary Fig. 4 ). Intracellular IL-2 staining of antigen-stimulated 8.3-CD8 + T cells or PMA/ ionomycin-stimulated nontransgenic CD8 + T cells demonstrated that the Idd3 B6/B6 genotype promotes the production of detectable IL-2 in a higher fraction of cells than for the Idd3 NOD/NOD genotype ( Supplementary Fig. 5 online). Analysis of Il2 pre-mRNA yielded genotype-dependent expression differences between 8.3-NOD and 8.3-NOD.Idd3 B6/B6 cells (Fig. 3d) . Allele-specific assays using purified 8.3-CD8 + T cells from TCRtransgenic (NOD Â NOD.B6 Idd3) F1 mice confirmed that the T1D-resistant B6 Il2 allele is transcriptionally more active than the NOD allele (Fig. 3e) . Thus, differential production of Il2 pre-mRNA from the protective and susceptible Il2 alleles is most likely caused by one or more cis-acting SNPs. In contrast to findings for Il2, we did not observe any differences in Il21 transcription ( Supplementary Fig. 4 ).
Il2 haplodeficiency recapitulates Idd3 susceptibility Notwithstanding the fact that the above differences in Il2 transcription are twofold and close to the technical resolution of the expression assays, many human diseases are due to haploinsufficiency or twofold differences in gene expression 19 . When we considered the implications of the Il2 gene sequencing and expression data, it was clear that although the data were correlated, another gene in the Idd3 region could still be causing the disease phenotype. An obvious experimental strategy would be to replace a susceptible Il2 allele with a resistant one, or vice versa. However, consideration of the following two possibilities prompted us to choose an alternative, potentially more informative approach: (i) the expression differences observed could be caused by a combination of multiple disease-causing SNPs affecting chromatin accessibility, and (ii) the disease-associated SNPs could extend beyond the B16-kb region for which we defined disease-associated SNPs. Therefore, in order to test the hypothesis that Idd3 is Il2, we took advantage of the fact that a 50% reduction in IL-2 production can be achieved without altering any of the other genes in Idd3, based on our findings that the NOD and 129 strains are IBD at Idd3 (Supplementary Fig. 1 ) and afford similar T1D susceptibilities 7 . We introduced one dose of a susceptible Idd3 region carrying a targeted mutation of Il2 (produced in 129 embryonic stem cells 20 with the resulting targeted strain backcrossed to the NOD strain) into 8.3-NOD mice carrying one copy of the protective B6 Idd3 region (Fig. 4a) . As expected, activated splenic 8.3-CD8 + T cells from Il2-hemizygous 8.3-NOD.Idd3 B6/NOD-IL-2null mice produced B50% less IL-2 ( Fig. 4b ) and contained fewer (roughly half) as many IL-2+ T cells as were isolated from 8.3-NOD.Idd3 B6/NOD mice ( Supplementary Fig. 5) . Similar approximately twofold differences in IL-2 expression were also noted with PMA/ionomycin-stimulated NOD.Idd3 B6/NOD-IL-2null and NOD.Idd3 B6/NOD splenic CD8 + T cells (Supplementary Fig. 5) . Notably, 8.3-NOD.Idd3 B6/NOD-IL-2null mice developed a significantly higher frequency of T1D than 8.3-NOD.Idd3 B6/NOD mice (Fig. 4c) . The B50% decrease in IL-2 production also accelerated T1D in nontransgenic NOD.Idd3 NOD/NOD-IL-2null mice (Fig. 4d) and abrogated the diabetes resistance afforded by one copy of the B6 Idd3 allele, thereby causing the diabetes frequencies of NOD.Idd3 B6/NOD-IL-2null and NOD mice to become nonstatistically different (Fig. 4e,f) . We therefore conclude that Il2 is a major component of Idd3.
Idd3 and the function of autoreactive CD8 + T cells Enhanced production of IL-2 from the B6 Idd3 allele had a marked effect on the ability of 8.3-CD8 + T cells to differentiate into cytotoxic effectors in vitro and in vivo. Naive CD8 + T cells purified from the spleens of 8.3-NOD.Idd3 B6/B6 and 8.3-NOD.Idd3 B6/NOD mice differentiated into cytotoxic T lymphocytes (CTLs) within 3 d of antigenic stimulation in vitro, whereas 8.3-CD8 + T cells purified from 8.3-NOD mice did not (Fig. 5a) . We observed similar differences in cytotoxicity between CD8 + T cells from recombination-activating gene ( mice, which have a monoclonal T cell repertoire lacking CD4 + T cells and B lymphocytes (Fig. 5b ). These differences in cytolytic potential were probably a direct consequence of differences in IL-2 secretion by the CTL precursors, for two reasons: 8.3-NOD.Rag2 -/--derived CD8 + T cells stimulated in the presence of recombinant mouse IL-2 (rmIL-2) acquired cytolytic activity in an IL-2 dose-dependent manner (Fig. 5b) , and addition of a blocking monoclonal anti-IL-2 to cultures of 8.3-NOD.Idd3 B6/B6 /Rag2 -/--derived CD8 + T cells inhibited the generation of effectors, also in a dose-dependent manner (Fig. 5b) . Thus, Idd3 regulates the differentiation of naive CD8 + T cells into CTL via differential expression of IL-2. Although naive 8.3-CD8 + T cells can trigger T1D in the absence of CD4 + T cells, they are more diabetogenic in their presence 12, 21 . As a result, 8.3-NOD.Rag2 -/-mice develop T1D less frequently than 8.3-NOD.Rag2 + mice (Fig. 5c) . Notably, introduction of a Rag2 deficiency into 8.3-NOD.Idd3 B6/B6 mice markedly increased the frequency of T1D as compared with that seen in both 8.3-NOD.Rag2 -/-and Rag2 + 8.3-NOD.Idd3 B6/B6 mice (Fig. 5c) . Because IL-2 has a key role in the development and function of CD4 + CD25 + regulatory T cells (Treg cells), one interpretation of these data is that increased production of IL-2 from the B6 Idd3 haplotype, in the absence of the ability to generate Treg cells in a Rag2-deficient setting, allows the CD8 + T cells to be even more pathogenic, fueled by their own IL-2. Therefore, we investigated the role of Treg cells in a possible regulatory feedback loop initiated by IL-2-producing CTLs.
Idd3 controls Treg function and recruitment
To determine whether Idd3 controls the size and/or function of the CD4 + CD25 + Treg pool, we examined mesenteric (MLN) and pancreatic lymph nodes (PLN) of 8.3-NOD.Idd3 B6/B6 mice and found that they had higher percentages (but not absolute numbers) of CD4 + CD25 + and FoxP3 + CD4 + T cells than 8.3-NOD mice (Fig. 6a and data not shown). These relatively small differences in the peripheral frequency of Treg cells were not a peculiarity of TCR-transgenic mice, as we also observed them between NOD and NOD.B6 Idd3 or NOD.CZECH Idd3 mice ( Supplementary Fig. 6 online). These CD4 + CD25 + T cells had the hallmarks of Treg cells 22 ( Supplementary  Fig. 7 online), and after activation with anti-CD3 and recombinant IL-2 (rIL-2) for 2 d 23 , they suppressed 8.3-CD8 + T cell IFNg responses induced by peptide-pulsed antigen presenting cells (APCs) in vitro ( Fig. 6b and Supplementary Fig. 6 ). (Fig. 6b , Supplementary Fig. 6 and data not shown). There were no differences in the FoxP3 + T cell content or in the mean fluorescence intensity (MFI) for FoxP3 in the CD4 + CD25 + T cell populations of 8.3-NOD.Idd3 B6/B6 versus 8.3-NOD mice (77% ± 5% versus 72% ± 6% FoxP3 + , respectively; MFI: 111 ± 9 versus 108 ± 6, respectively), suggesting that these Idd3-associated, interstrain differences in suppressive activity were not due to a quantitative difference in the number of Treg cells added. Similar results were obtained with the CD4 + CD25 + T cell populations of NOD.Idd3 B6/B6 versus NOD mice (80% ± 7% versus 79% ± 4% FoxP3 + , respectively; MFI: 97 ± 11 versus 107 ± 12, respectively). In addition, these differences in suppressive activity were not caused by differences in the diabetes susceptibility of the strains that were compared, as the CD4 + CD25 + T cells of B10.BR mice were also more suppressive than those of the diabetes-resistant, NOD Idd3-congenic strain, B10.BR Idd3 NOD/NOD ( Supplementary Fig. 6 ). We made similar observations in vivo: a single injection of a small number (2 Â 10 5 cells) of CD4 + CD25 + T cells from NOD.B6 Idd3 (but not NOD) mice suppressed diabetes in 8.3-NOD.Rag2 -/-mice ( Supplementary Fig. 6 ). Activation and recruitment of 8.3-like CD8 + T cells to the pancreas is preceded by cross-presentation of beta cell autoantigen by dendritic cells in the PLNs 24 . We have previously shown that CD4 + CD25 + Treg cells inhibit 8. (Fig. 6c) . These differences in proliferation were not due to differences in the size of the autoantigen-load carried by the dendritic cells, because they persisted upon pulsing with NRP-A7 ex vivo (Fig. 6d) . Hence, the Idd3-encoded increase in Treg function in NOD.B6 Idd3 mice is associated with decreased cross-presentation of beta cell autoantigens to autoreactive CD8 + T cells in the PLNs.
IL-2 production in response to antigenic stimulation is known to promote the recruitment and activation of CD4 + CD25 + Treg cells 25, 26 . The above data suggested that, by producing higher levels of IL-2, autoantigen-activated autoreactive CD8 + T cells from NOD.B6 Idd3 mice might be able to more efficiently induce or recruit CD4 + CD25 + Treg cells to the PLNs. To test this possibility, we transferred naive splenic 8.3-CD8 + T cells from 8.3-NOD or 8.3-NOD.Idd3 B6/B6 mice into NOD hosts. One day after transfer, we injected the hosts in the footpads with soluble NRP-A7 in the absence of adjuvant to synchronize antigen-induced activation of the donor cells in the host lymph nodes. The absolute number of CD4 + CD25 + or FoxP3 + CD4 + T cells contained in the PLNs of the mice transfused with CD8 + T cells from 8.3-NOD.Idd3 B6/B6 mice was significantly higher than that seen in the hosts transfused with T cells from 8.3-NOD mice (Fig. 6e) . The numbers of FoxP3 + CD4 + T cells contained in the MLNs of the former mice were also higher, although the differences were not statistically significant (6 ± 1 versus 3.9 ± 1 Â 10 5 ). Hence, the amount of IL-2 produced by autoreactive CD8 + T cells in response to exogenous antigen seems to control the size of the lymph node Treg pool.
Il2 haplodeficiency decreases Treg function
These results begged the question of whether the Idd3-encoded control of Treg function and recruitment and altered autoantigen crosspresentation are consequences of the Idd3-encoded differences in IL-2 production. In agreement with this idea, the PLNs and MLNs of 8.3-NOD.Idd3 B6/NOD-IL-2null mice and nontransgenic NOD.Idd3 B6/NOD-IL-2null mice, compared with 8.3-NOD.Idd3 B6/NOD and NOD.Idd3 B6/NOD mice, respectively, harbored significantly lower percentages (but not absolute numbers) of FoxP3 + CD4 + T cells (Fig. 7a,b) and CD4 + CD25 + T cells with lower suppressive ability (Fig. 7c) . These data are consistent with the observation above that the frequencies of T1D were significantly higher in 8.3-NOD.Idd3 B6/NOD-IL-2null mice than in 8.3-NOD.Idd3 B6/NOD mice and higher in NOD.Idd3 B6/NOD-IL-2null mice than in NOD.Idd3 B6/NOD mice (Fig. 4c,e) .
DISCUSSION
Our data indicate that the NOD haplotype of Il2 SNPs predisposes to organ-specific autoimmune disease by reducing IL-2 production from antigen-specific T cells. This correlates with the impairment of a putative feedback mechanism initiated by activated, IL-2-producing autoreactive T cells that increases CD4 + CD25 + Treg activity. We hypothesize that in the presence of protective Idd3 alleles, these activated CD4 + CD25 + Treg cells interact with dendritic cells 27 , suppress dendritic cell maturation 23 and inhibit the cross-presentation of beta cell autoantigens to autoreactive T cells 23 , thereby maintaining homeostatic control of autoreactive T cells and preventing disease progression.
The results of previous disease frequency studies in non-TCRtransgenic Idd3 strains demonstrated that protection caused by the B6 Idd3 allele is dose dependent rather than dominant or recessive 3 . This interpretation is compatible with the seemingly dominant protective effect of this allele in the 8. It has recently been suggested that Il21 could be Idd3, with a report that NOD mice have reduced T cell numbers and that their autoimmune susceptibility may be the result of exaggerated homeostatictype proliferation driven by IL-21, a cytokine produced by activated T cells 8 . Based on our data, we propose that the reported expression variation of Il21 is either secondary to the genetic alterations in IL-2 production described here or is intrinsic to Il21, but that Il21 is not the primary genetic determinant of Idd3 influencing T1D susceptibility.
Although we cannot rule out the possibility that the etiological Idd3 'mutation' occurs in only one of the 46 disease-associated SNPs, we favor the hypothesis that it corresponds to at least several SNPs that affect the competency to produce IL-2 and/or the rate of transcription. In support of this hypothesis, 33 of the 46 disease-associated SNPs are located in a segment of DNA that extends 10 kb upstream of the known Il2 promoter (Supplementary Fig. 1 ). This 5¢ region of Il2 has locus control region-like activity that determines the competency of a cell to express Il2 mRNA. This region undergoes specific epigenetic changes during both development and activation that regulate locus accessibility and recruitment of the transcription machinery 11, 30, 31 .
It has been shown that there is intrinsic variability in IL-2 commitment within clonal T cell populations 32 . Thus, increased production of IL-2 by the B6 Idd3 allele in activated T cells could be due to (i) faster transcription of Il2 on a per-cell basis owing to improved accessibility of transcription factors to the resistance allele and/or (ii) an increase in the fraction of cells that actively produce IL-2 upon making stable contacts with dendritic cells, owing to a reduction in the threshold of remodeling required by the resistance allele to enable transcription. Although our intracellular IL-2 staining data suggest that the latter mechanism is at play, additional studies are required.
Overall, our observations indicate that all or most of the effect of Idd3 is explained by variation in Il2, linking Idd3 activity with the activity of CD4 Treg cells expressing CD25 (IL-2Ra). In human T1D, susceptibility has been mapped to the gene encoding the IL-2Ra chain, IL2RA (also known as CD25; ref. 33 ). The differentiation, activation and homeostasis of CD4 + CD25 + Treg cells is highly dependent on CD25 function and IL-2 signaling 25, 26, [34] [35] [36] [37] [38] [39] . Targeted disruption of the genes encoding IL-2 or the a or b chains of IL-2R in mice causes autoimmune disease [40] [41] [42] , as does mutation of the gene encoding the a chain of IL-2R in humans 43 . A potential relevance of our results to human T1D is suggested by reports of reduced Treg number and/or function in individuals with T1D [44] [45] [46] . Based on all of these observations, it is evident that spontaneous development of organ-specific autoimmunity is critically dependent on the physiological regulation of T cell activation and expansion and that in genetically susceptible subjects with a lower set point of immune homeostasis, a modest increase in IL-2R signaling may reduce the risk of disease.
METHODS
Mice. The NOD.B6 Idd3 congenic strain used in this study has been described previously 4 . It has a 2.8-Mb interval introgressed from the B6 strain and is available from the Taconic Emerging Models Program as line 1098 (see URLs section below). The NOD.129 Idd3 congenic strain has also been described previously 7 ; it shows a NOD-like susceptibility to diabetes and has a 129-derived congenic interval from D3Mit93 (29.3 Mb) to D3Mit65 (50.8 Mb). New Idd3-congenic mice were produced by introgressing Idd3 alleles onto the NOD background as described previously 2,3 using the CZECH, SWR, A/J and CASTANEOUS inbred strains (obtained from The Jackson Laboratory). The NOD.CZECH Idd3 congenic strain was developed using a 'speed congenic' strategy in which evenly spaced NOD/CZECH polymorphisms from throughout the genome 47 (including locations having known Idd loci) were tested to select breeders having the greatest level of NOD homozygosity at each generation, except at the Idd3 region (selected congenic interval: D3Mit329/ 23.0 Mb to D3Mit274/51.4 Mb). After an intercross at N6 to obtain NOD. CZECH Idd3 mice homozygous for the CZECH allele, at which time all tested non-Idd3 loci were NOD homozygous, we performed a T1D frequency study. This study was done in 1999 at Merck Research Laboratories contemporaneously with the NOD and NOD.B6 Idd3 strains (Fig. 1a) . This NOD.B6 Idd3 strain was subsequently transferred to the University of Calgary for introgression of the 8.3-TCR transgenes. To develop the NOD strains congenic for the Idd3 regions of SWR, A/J and CASTANEOUS, mice were backcrossed to the NOD strain, and at the N6 generation all three strains were confirmed to be NOD homozygous at Idd1, Idd4, Idd5, Idd6, Idd9, Idd10, Idd17 and Idd18 (ref. 1). A disease frequency study conducted in 2004-2005 at Merck Research Laboratories was then initiated using Idd3 heterozygous males and females to produce an F2 cohort for each of the three Idd congenic strains. This methodology was used to avoid testing the remainder of the genome of the three new Idd3 congenic strains for non-NOD homozygous segments. All progeny (NOD at Idd3, heterozygous at Idd3 and homozygous non-NOD at Idd3) were monitored for disease frequency and genotyped after developing T1D or at the end of the study. 8.3-NOD and 8.3-NOD.Rag2 -/-mice have been described previously 12 . NOD.Il2 +/-mice were generated by backcrossing a mutant Il2 allele (from 129.Il2 +/-mice) onto the NOD background at the Jackson Laboratory. Mice from the N10 backcross were sent to the University of Calgary for experimentation. The targeted chromosome 3 of this strain has a maximal 129-derived congenic interval from D3Mit118 (29.2 Mb) to D3Mit241 (66.6 Mb). The frequency studies shown in Figures 3-5 and Supplementary  Figure 6 were performed at the University of Calgary. All mice were housed in specific pathogen-free conditions. Experimental procedures were approved by the animal use and care committees of the University of Calgary, the University of Cambridge and Merck Research Laboratories.
SNP identification. NOD, 129 and B6 BAC sequences were aligned, and SNPs were identified using SSAHA 48 . The SNPs were entered into TIDBase 49 to generate graphic displays of the Idd3 region. Using these polymorphisms, new markers were developed by designing primers with Primer3 (see URLs section below) and were synthesized by Sigma Genosys, with the forward primer labeled with the fluorescent dye fam. For the haplotype analysis of Il2 and Il21, nested PCR primers were designed to span the region to be sequenced. Outer primers and inner primers generated 1,500-bp and 500-bp products, respectively, each overlapping by 50 bp to generate a continuous sequence. BigDye Terminator 3 (Applied Biosystems) was used to sequence the products. All sequences generated were entered into T1DBase for SNP identification and disease SNP haplotype mapping. The locations of known DNAse1 hypersensitivity sites in Il2 and Il21 ( Supplementary Fig. 1 online) were obtained from refs. 27 and 50, respectively.
Treatment with monoclonal anti-CD3. Mice were injected with 1 mg monoclonal anti-CD3 (clone 2C11, BioExpress) intravenously and were killed 90 min later. Spleens were immediately homogenized in 1.5 ml TRIzol (Invitrogen) using a polytron or were used in cell purification procedures.
Reverse transcription followed by quantitative PCR (RT-qPCR). Intronic and exonic RT-qPCR assays were performed in an ABI Prism 7700 using 1 mg of RNA and TaqMan One-Step RT-PCR Master Mix (Applied Biosystems). For the exon-based Il2 qPCR assay, we used a TaqMan kit from Applied Biosystems. qPCR for B2m (control) and Il21 were done using primers and probes designed in house and synthesized by Sigma Genosys. For intron-based assays, the RNA was treated with DNase. The effectiveness of DNase treatment was verified by analyzing samples in parallel that were not treated with reverse transcriptase (RT). For RT-negative samples, successful DNase treatment yielded Ct values equal to those obtained with water. Primer sequences are listed in Supplementary Table 1 online.
Pyrosequencing and quantification of allelic expression ratios. Total RNA from cells heterozygous at the Il2 locus was purified using TRIzol. The RNA was then treated with DNase using the RNeasy and RNase-Free DNase kits (Qiagen) following the manufacturer's instructions. DNase-treated RNA was used as a template for cDNA synthesis using SuperScript II reverse transcriptase (Invitrogen). Pyrosequencing (Biotagen) uses a sequencing method coupled to a luciferase enzyme/substrate reaction, which produces light each time a nucleotide is added in the sequencing reaction. The PSQ96 system (Biotage) calculates, from the amount of light generated, the relative abundance of that nucleotide within the sample. Previously identified SNPs within intron 2 of Il2 were used to design pyrosequencing assays. Forward and reverse PCR primers were designed against conserved sequences near a SNP to amplify a 150-200 bp PCR product. A pyrosequencing primer was designed using the pyrosequencing SNP primer design website (see URL below). The assays were performed according to the manufacturer's instructions. Genomic DNA standard curves generated from each strain represented in the F1 were used to normalize the cDNA results. Primer sequences are listed in Supplementary Table 1.
Diabetes. Diabetes was monitored by measuring urine glucose with Diastix (Miles Canada). Animals were considered diabetic after two consecutive readings Z3. The frequency of diabetes was compared between strains with the Kaplan-Meier log-rank test using Prism software (GraphPad).
Cell lines and antibodies. All monoclonal antibodies were from PharMingen, unless otherwise indicated. Anti-mouse GITR goat IgG and recombinant mouse IL-2 (rmIL-2) were from R&D Systems. Anti-FoxP3 (FJK-16s) was from eBioscience. Streptavidin-PerCP was from Becton-Dickinson. FITClabeled donkey anti-goat IgG, anti-hamster IgG biotin and streptavidin-Cy3 were from Jackson ImmunoResearch Laboratories.
